Navigation Links
Personalized medicine: Innovative online journal leads the way
Date:11/12/2008

The recent surge of DNA sequence information resulting from deciphering the human genetic code has acted as a catalyst for innovative technological developments that have been vital in the identification of genes associated with disease pathologies. This has allowed for the development of novel genetic therapies to treat a wide range of inherited disorders.

The new genomic era heralds earlier diagnoses, greatly improved prevention and treatment of diseases and enhanced avoidance of side effects from drugs.

Now, the latest information and findings that have an impact on the understanding and management of human health and disease will be available online to physicians around the globe with the launch of BioMed Central's premier medical journal Genome Medicine.

Today, Genome Medicine, an online peer-reviewed open access research journal will be launched at a special event at the 58th annual meeting of the American Society of Human Genetics (ASHG), in Philadelphia.

The launch issue is sponsored by Agilent, the electronic and bio-analytical measurement company. In addition to publishing high-quality research, Genome Medicine serves the international research community as a forum for the discussion and critical review of information about all areas of medicine informed by genomic research.

Genome Medicine will focus on the following areas:

  • Significant advances in the understanding of the genetics, genomics, and epigenetics of disease
  • Computational and systems approaches, including proteomics, metabolomics and transcriptomics, to the understanding and management of disease
  • Genomic epidemiology and public health genomics
  • The application of genomic and post-genomic technologies to clinical practice, with special emphasis on diagnostics and therapeutics
  • Personalized medicine
  • Ethical, social and legal issues relating to genomic medi
    '/>"/>

Contact: Matt McKay
matthew.mckay@biomedcentral.com
44-078-252-57423
BioMed Central
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. New genetic research into nicotine addiction shows promise for personalized treatment
2. Emory, Ohio State launch partnership in predictive and personalized health care
3. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
4. Researchers at UH explore patient preferences for personalized medicine
5. Telemedicine: Health alert via satellite
6. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
7. Innovative civil engineering application promises cleaner waters
8. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
9. NIST announces 56 new awards for innovative technology research and development
10. BIO-key International Showcasing Innovative Public Safety Solutions at 2007 IACP Conference
11. Einstein researchers receive grants totaling $700,000 for innovative breast cancer research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... majority owned subsidiary of Avisio, Inc. acquired an ... , The technology is based on an ... e.g. mosquitos and black flies, utilize their olfactory ... animals and humans. CO2, which is a major ... insect to its prey. , Developed by ...
(Date:2/8/2010)... Mediterranean diet may help people avoid the small areas ... thinking and memory, according to a study released today ... Neurology,s 62nd Annual Meeting in Toronto April 10 to ... people who ate a Mediterranean-like diet were less likely ... tissue linked to thinking problems. , The Mediterranean ...
(Date:2/8/2010)... With the recent election of Senator ... in the loss of the Democratic supermajority, the urgency ... universal coverage for the majority of uninsured Americans has ...  President Obama recently noted the country is closer than ... for many a long sought after social reform, and ...
Breaking Biology News(10 mins):Mediterranean diet may lower risk of brain damage that causes thinking problems 2S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 2S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 3S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 4S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 5S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 6S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 7S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 8S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 9Census Bureau Releases Comprehensive Health Insurance Coverage Estimates by County 53506 1Census Bureau Releases Comprehensive Health Insurance Coverage Estimates by County 53506 2Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 1Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 2Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 3Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 4Exercise Is Healthy for Mom and Child During Pregnancy 53502 1Exercise Is Healthy for Mom and Child During Pregnancy 53502 2Exercise Is Healthy for Mom and Child During Pregnancy 53502 3
... reported findings that offer a surprising new twist to ... select the flowers from which they collect nectar. When ... flowers entirely alone but instead copy the choices of ... their behavior when dealing with flowers of unfamiliar plant ...
... paths some 5 million to 6 million years ago, we ... and acquired a knack for abstract thought while our next ... to construct tree-bound nests high above the forest floor. We ... sequence level, yet scientists predict that both species should harbor ...
... River varies in time, what causes those variations, and ... deforestation is a focus of study for scientists at ... in the last several decades have led to significant ... eastern and southern portion of the basin. By using ...
Other Biology News:Can our genes tell the story of our divergence? 2Assessing the Amazon River's sensitivity to deforestation 2
(Date:2/9/2010)... Feb. 9 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.,(NYSE ... an international,biopharmaceutical company with operations in the U.S. ... cell collection network has expanded into the southwestern,region ... physician group at Westlake,Orthopaedics Spine & Sports ("Westlake") ... is on,track to achieve its target of 10 ...
(Date:2/8/2010)... /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., (NYSE Alternext: TPI), ... based in Chengdu, China ,today announced fiscal results ... . , , -- Q2 2010 ... 24.8% to $2.6 ... basis, -- Cash and Equivalents of ...
(Date:2/8/2010)... label-free biomolecular interaction analysis now offers surface chemistries for: ... and Protein G for coupling antibodies. , ... ... February 8, 2010 -- Silicon Kinetics Inc., the pioneering ... first 3D biosensor surface for label-free biomolecular interaction analysis, ...
(Date:2/8/2010)... NEW ORLEANS , Feb. 8 /PRNewswire-FirstCall/ ... worldwide developer and marketer of diagnostic test kits, and ... of the collaborative effort to combat viral hemorrhagic fever ... $800,000 in contract revenue for Corgenix over the ... of Health (NIH) has awarded a five-year contract totaling ...
Breaking Biology Technology:Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network 2Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network 3Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network 4Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 2Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 3Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 4Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 5Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 6Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 7Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 8Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 9Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 10Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 11Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 12Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 13Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 14Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 15Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 16Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 17Silicon Kinetics Announces New Biosensor Chips With Wide Palette of Surface Chemistries 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 3Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 4Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 5Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 6Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 7
... Nov. 26 Evalve, Inc., the leader in,the ... cardiac valves,announced today that the first three patients ... the University of Hull, Castle Hill Hospital,in the ... commercially,available medical device which provides a non-surgical mitral ...
... an update on internal policy and clinical, ... Symbol: RVX , , CALGARY, ... that the previously announced internal blackout trading restriction of April ... regional and global partnerships are actively ongoing and should the ...
... Nov. 26 Thomas K. Equels, President and Managing,Director ... the board of directors,for Hemispherx BioPharma, Inc. (Amex: ... manufacture and clinical development,of new drug entities for the ... Equels, legal practice is devoted ...
Other Biology Technology:First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 2First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 3Resverlogix Board of Directors Update 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 3
...
...
... allow for the rapid isolation of DNA from ... slice in the spin filter, centrifuge for 3 ... recovered. There is no need to melt agarose ... can also be used for buffer exchange, primer ...
ChemiArray Human Cytokine Antibody Array VII, 60 cytokines per membrane...
Biology Products: